Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term dalteparin study in cancer patients with symptomatic venous thromboembolism
2008-005236-32Phase 4Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dalteparin in venous thromboembolism (VTE) and cancer, sponsored by Eisai Co., Ltd. Primary endpoints: Major bleeding event rate and Central Adjudication Committee assessment of venous thromboembolism. Started Dec 2008; status: completed.
02
Drugs
dalteparin
03
Conditions
venous thromboembolism (VTE)cancer
Beyond the preview
Go deeper on 2008-005236-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005236-32.